Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW. · 2016

Read Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. by van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4755228.txt.

Introduction

Niels W. C. J. van de Donk leads eight authors in an Immunological Reviews survey from 2016 on antibody drugs aimed at CD38. CD38 is a surface protein found at low levels on many blood cells but in rich supply on plasma cells. Cancers of plasma cells, above all multiple myeloma, carry it in bulk.

The review covers three drugs in the class and how they kill. They call in immune attack, trigger cell death, and blunt the protein's enzyme work. Early patient data show strong action against myeloma with mild side effects. That mild profile lets doctors pair them with older drugs. The authors also flag trials in other blood cancers and possible uses in solid tumors and immune disease.

Catalog record

CREATORvan de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE89 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4755228

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond By Niels W. C. J. van de Donk, Maarten L. Janmaat, Tuna Mutis, Jeroen J. Lammerts van Bueren, Tahamtan Ahmadi, A. Kate Sasser, Henk M. Lokhorst, Paul W. H. I. Parren Published in: Immunological Reviews DOI: 10.1111/imr.12389 ABSTRACT Summary CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on various hematological and solid tissues, while plasma cells express particularly high levels of CD38. The protein is also expressed in a subset of hematological tumors, and shows especially broad and high expression levels in plasma cell tumors such as multiple myeloma (MM). Together, this triggered the development of various therapeutic CD38 antibodies, including daratumumab, isatuximab, and MOR202. Daratumumab binds a unique CD38 epitope and showed strong anti‐tumor activity in preclinical models. The antibody engages diverse mechanisms of action, including complement‐dependent cytotoxicity, antibody‐dependent cellular cytotoxicity, antibody‐dependent cellular phagocytosis, programmed cell death, modulation of enzymatic activity, and immunomodulatory activity. CD38‐targeting antibodies have a favorable toxicity profile in patients, and early clinical data show a marked activity in MM, while studies in other hematological malignancies are ongoing. Daratumumab has single agent activity and a limited toxicity profile, allowing favorable combination therapies with existing as well as emerging therapies, which are currently evaluated in the clinic. Finally, CD38 antibodies may have a role in the treatment of diseases beyond hematological malignancies, including solid tumors and antibody‐mediated autoimmune diseases. This article is part of a series of reviews covering Immunoglobulins: from genes to therapies appearing in Volume 270 of Immunological Reviews. CD38: THE TARGET CD38, in the past referred to as T10, was identified in 1980 in a project investigating cell surface molecules of human leukocytes using thymocyte‐specific murine monoclonal antibodies 1. In the early days, CD38 was recognized as a differentiation and activation marker of lymphocytes, later it was used as a phenotypic marker in the classification of T‐ and B‐cell malignancies, and identified as a promising target for antibody‐based therapies. It was also found that CD38 has multiple receptor and enzymatic functions. Here, we bring all these aspects of CD38 together, and give our perspective on CD38‐targeted therapy. The CD38 gene The human CD38 gene is located on chromosome 4 (4p15) and stretches over 62 kb. The gene comprises seven introns, which represent the vast majority (>98%) of the gene, and eight exons that encode the CD38 protein 2. Gene transcription is regulated at multiple levels. The promoter region is characterized by the presence of CpG islands that are controlled by methylation, but lacks canonical TATA and CAAT boxes 3. Potential binding sites for various immunological transcription factors, including those for T cell‐specific transcription factor alpha (TCF‐1α), nuclear factor‐IL‐6 (NF‐IL‐6), and interferon responsive factor‐1 (IRF‐1) are located upstream of these CpG islands 3. Tumor necrosis factor‐alpha (TNFα), for example, has been shown to mediate interferon‐dependent induction of CD38 expression in airway smooth muscle cells 4, and IFNγ upregulates expression and activity of CD38 in human monocytes 5. Another level of transcriptional control is positioned within intron 1, which contains responsive elements for retinoic acid (RA) 6 and peroxisome proliferator‐activated receptor γ (PPARγ) 7. Interestingly, in vivo upregulation of CD38 via the RA receptor signaling pathway was observed in patients with promyelocytic leukemia following a single oral administration of RA 6, 8, 9. Finally, the transcription factor E2A mediates CD38 gene transcription in response to environmental signals, such as interleukin‐2 and TLR‐9 ligands 10. Transcription initiation by E2A is affected by the presence of a single nucleotide polymorphism (SNP) at the 5′‐end of intron 1, which is located within a putative E‐box 10, 11, 12. The presence of a guanine (G) instead of a cytosine (C) at this position, which is present in approximately 14% of the healthy Caucasian population, enhances CD38 transcription and results in increased protein expression levels 10, 11. Of note, the frequency of this relatively rare G allele was significantly higher in a subset of chronic lymphocytic leukemia (CLL) patients with markers of poor prognosis 10. CD38 protein structure The human CD38 antigen is a 46‐kDa type II transmembrane glycoprotein. The primary and secondary structure of CD38 exhibits a striking similarity (approximately 35% amino acid identity) to a soluble cyclase that was identified from the mollusk Aplysia californica 13, 14. CD38 contains a relatively long C‐terminal extracellular domain (258 aa), a transmembrane region (21 aa) and a short N‐terminal cytoplasmic tail (21 aa) 15. The protein is stabilized by six disulfide bonds and has four potential N‐linked glycosylation sites. The crystal structure of the CD38 extracellular domain has been resolved to 1.9 Å, revealing that the protein's overall topology is similar to the related proteins CD157 and the Aplysia ADP‐ribosyl cyclase, except for large structural differences at the two termini 16. Further biochemical observations indicated the existence of a CD38 tetramer on the cell surface 17, 18, 19. Tetramerization was suggested to be required for the CD38 catalytic activity and the localization of CD38 in lipid rafts 20. In addition to the cell membrane‐bound form, a 39‐kDa soluble variant of CD38 has been found in biological fluids 21, and a 78‐kDa soluble form was identified from cells of X‐linked agammaglobulinemia patients 19. CD38: the receptor Early functional studies showed that CD38 regulates weak adhesion events that take place between circulating lymphocytes and endothelial cells 22. This finding was key in identifying a receptor function for CD38. A murine mAb raised against HUVEC blocked CD38‐mediated adhesion of several cell lines to HUVEC 23. By resolving the target of this blocking mAb, CD31 was identified as a ligand for CD38 24. CD31 (also known as PECAM‐1) is a member of the Ig gene superfamily characterized by six Ig‐like domains 25. In addition to its expression on endothelial cells, CD31 is expressed on lymphoid cells (follicle mantle B cells and plasma cells), in the lungs (alveolar ducts, alveoli, and lymphatic vessels), and in the kidney (glomerular cells) 26. The CD38–CD31 interaction does not only play a role in the binding and migration of leukocytes through the endothelial cell wall but also triggers activation and proliferation of human leukocytes 24, 27. Moreover, the adhesion function of CD38 is involved in the differentiation of B cells, which requires heterotypic interactions as a crucial developmental step. CD38: the ecto‐enzyme Next to its receptor function, CD38 has bifunctional ecto‐enzymatic activity 28, 29. The protein has cyclase as well as hydrolase activity. Similar to its Aplysia homolog, CD38 uses NAD+ as substrate for the formation of cyclic ADP‐ribose (cADPR) and ADPR. Indeed, studies in CD38 knockout mice showed that CD38 is indispensable for NAD+‐glycohydrolase activity in the liver and brain 30. In acidic conditions, CD38 in addition catalyzes the generation of nicotinic acid‐adenine dinucleotide phosphate (NAADP+) from nicotinamide adenine dinucleotide phosphate (NADP+) 29, 31, 32. cADPR, ADPR, and NAADP+ are potent second messengers that regulate Ca2+ mobilization from the cytosol 33, activating signaling pathways that control various biological processes, such as lymphocyte proliferation 34 and insulin secretion by β‐cells in the pancreas 35, 36, 37. Interestingly, recent studies suggest a pivotal role of CD38‐dependent adenosine production in immune suppression mediated by natural killer (NK) cells 38

Read the complete text